Literature DB >> 23474745

Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis.

Andor W J M Glaudemans1, Riemer H J A Slart, Walter Noordzij, Rudi A J O Dierckx, Bouke P C Hazenberg.   

Abstract

PURPOSE: Amyloidosis is a group of diseases characterized by deposition of fibrils and this deposition may be localized or systemic. The presence of giant cells is typical of localized AL amyloidosis in contrast to systemic amyloidosis. Because of this presence of giant cells we hypothesize that (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) may show uptake in localized amyloidosis but not in systemic amyloidosis. The aim of the study was to evaluate the utility of (18)F-FDG PET/CT in distinguishing systemic amyloidosis from localized amyloidosis.
METHODS: A retrospective search in the hospital computer system showed 21 patients with histologically proven systemic or localized amyloidosis who recently had undergone (18)F-FDG PET/CT. Twenty patients also had undergone (123)I-serum amyloid P component (SAP) scintigraphy.
RESULTS: Of 11 patients with localized amyloidosis, 10 showed markedly increased FDG uptake at the amyloid site, whereas one showed slightly increased FDG uptake. (123)I-SAP scintigraphy (in ten patients) was positive in three patients at the amyloid site and negative for any other specific organ involvement in nine patients, with a weakly positive spleen in one other patient. In ten patients with systemic amyloidosis, increased FDG uptake was not found in any affected organ containing amyloid, whereas (123)I-SAP scintigraphy was positive for specific organ involvement in nine patients.
CONCLUSION: (18)F-FDG PET/CT may be supportive of the usual diagnostic tests in differentiating between systemic amyloidosis (no increased FDG uptake at the amyloid site) and localized amyloidosis (increased FDG uptake at the amyloid site). Apart from diagnosis, this finding has potential clinical application in therapy evaluation and follow-up.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474745     DOI: 10.1007/s00259-013-2375-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  False-positive FDG positron emission tomography in pulmonary amyloidosis.

Authors:  Glenn P Ollenberger; Simon Knight; Andrew J Tauro
Journal:  Clin Nucl Med       Date:  2004-10       Impact factor: 7.794

2.  Intestinal amyloidosis: two cases with different patterns of clinical and imaging presentation.

Authors:  Pier-Paolo Mainenti; Sabrina Segreto; Marcello Mancini; Antonio Rispo; Immacolata Cozzolino; Stefania Masone; Ciro-Roberto Rinaldi; Gerardo Nardone; Marco Salvatore
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

3.  Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.

Authors:  M Botto; P N Hawkins; M C Bickerstaff; J Herbert; A E Bygrave; A McBride; W L Hutchinson; G A Tennent; M J Walport; M B Pepys
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

4.  Lymphadenopathy due to amyloidosis secondary to Sjögren syndrome and systemic lupus erythematosus detected by F-18 FDG PET.

Authors:  Itsuko Serizawa; Masayuki Inubushi; Kakuko Kanegae; Koichi Morita; Tetsuya Inoue; Tohru Shiga; Tomoo Itoh; Jun Fukae; Takao Koike; Nagara Tamaki
Journal:  Clin Nucl Med       Date:  2007-11       Impact factor: 7.794

5.  Fixed digital contractures revealing light-chain amyloidosis.

Authors:  Félicie Costantino; Damien Loeuille; Hervé Dintinger; Patrice Péré; Isabelle Chary-Valckenaere
Journal:  Joint Bone Spine       Date:  2009-10-02       Impact factor: 4.929

6.  Findings of pulmonary amyloidosis on dual phase FDG PET/CT imaging.

Authors:  Haibo Tan; Yihui Guan; Jun Zhao; Xiangtong Lin
Journal:  Clin Nucl Med       Date:  2010-03       Impact factor: 7.794

Review 7.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

8.  Pulmonary amyloidosis mimicking multiple metastatic lesions on F-18 FDG PET/CT.

Authors:  Ji Hyoung Seo; Sang Woo Lee; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Lung Cancer       Date:  2010-03       Impact factor: 5.705

9.  Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.

Authors:  P L Jager; B P Hazenberg; E J Franssen; P C Limburg; M H van Rijswijk; D A Piers
Journal:  J Nucl Med       Date:  1998-04       Impact factor: 10.057

Review 10.  Amyloidosis.

Authors:  Mark B Pepys
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

View more
  23 in total

1.  Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition.

Authors:  Neha Mehta; Heiko Schöder; April Chiu; John Kenneth Schoolmeester; Carol Portlock
Journal:  BMJ Case Rep       Date:  2014-11-14

2.  Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.

Authors:  Joo Hee Lee; Ga Yeon Lee; Seok Jin Kim; Ki Hyun Kim; Eun-Seok Jeon; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2015-05-13

Review 3.  The Prevalence and Management of Systemic Amyloidosis in Western Countries.

Authors:  Hans L A Nienhuis; Johan Bijzet; Bouke P C Hazenberg
Journal:  Kidney Dis (Basel)       Date:  2016-02-25

Review 4.  The Potential of Metabolic Imaging.

Authors:  Valentina Di Gialleonardo; David M Wilson; Kayvan R Keshari
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

Review 5.  Nuclear imaging for cardiac amyloidosis.

Authors:  Walter Noordzij; Andor W J M Glaudemans; Simone Longhi; Riemer H J A Slart; Massimiliano Lorenzini; Bouke P C Hazenberg; Claudio Rapezzi
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 6.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

7.  Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases.

Authors:  Hisanori Kinoshita; Hodaka Yamakado; Toshiyuki Kitano; Akihiro Kitamura; Hirofumi Yamashita; Masakazu Miyamoto; Takefumi Hitomi; Tomohisa Okada; Yuji Nakamoto; Nobukatsu Sawamoto; Akifumi Takaori-Kondo; Ryosuke Takahashi
Journal:  J Neurol       Date:  2016-06-10       Impact factor: 4.849

Review 8.  Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT.

Authors:  Ryogo Minamimoto
Journal:  Jpn J Radiol       Date:  2021-01-31       Impact factor: 2.374

9.  Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report.

Authors:  JianJie Wang; Bin Zhao; Tianbin Song; Jidong Sun
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

10.  Amyloid arthropathy in smoldering myeloma: Do not take it lightly.

Authors:  Eli Muchtar; Rebecca L King; Ellen D McPhail; Matthew P Thorpe; Wilson Gonsalves; Floranne Ernste; Martha Grogan; Angela Dispenzieri; Morie A Gertz
Journal:  Leuk Res Rep       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.